sr141716 has been researched along with Depression in 33 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 24 (72.73) | 29.6817 |
2010's | 9 (27.27) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Stavreva, GT; Tashev, RE; Velikova, MS | 1 |
Butler, P; Munafò, MR; Nutt, DJ; Robinson, ES; Stuart, SA | 1 |
Baldaia, MA; Berro, LF; Frussa-Filho, R; Hollais, AW; Longo, BM; Marinho, EA; Oliveira-Lima, AJ; Patti, CL; Santos, R; Takatsu-Coleman, AL; Wuo-Silva, R; Yokoyama, TS | 1 |
Antoniou, K; Delis, F; Gueye, AB; Laviolette, SR; Le Foll, B; Loureiro, M; Makriyannis, A; Poulia, N; Pryslawsky, Y; Trigo, JM; Vemuri, K | 1 |
Joca, SRL; Kirkedal, C; Liebenberg, N; Moreira, F; Wegener, G | 1 |
Kapoor, S | 1 |
Chaput, JP; Tremblay, A | 1 |
Soyka, M | 1 |
Aronne, LJ; Davis, SN; Foster, GD; Pagotto, U | 1 |
Faludi, G; Halmy, L; Purebl, G; Rihmer, Z | 1 |
Gorzalka, BB; Hill, MN | 1 |
Kim, DH; Lee, S; Ryu, JH; Yoon, SH | 1 |
Browning, M; Cowen, PJ; Di Simplicio, M; Harmer, CJ; Horder, J | 1 |
Assareh, N; ElBatsh, MM; Kendall, DA; Marsden, CA | 1 |
Boggs, DL; Buchanan, RW; Conley, RR; Gold, JM; Gorelick, DA; Huestis, MA; Kelly, DL; Linthicum, J; Liu, F; McMahon, RP; Waltz, J | 1 |
Elbatsh, MM; Kendall, DA; Marsden, CA; Moklas, MA | 1 |
Borrelli, F; Capasso, F; Capasso, R; Izzo, AA; Mascolo, N | 1 |
Griebel, G; Scatton, B; Stemmelin, J | 1 |
Gadde, KM | 1 |
Roberfroid, D | 1 |
Cahill, K; Ussher, M | 2 |
Holsboer, F; Lutz, B; Marsicano, G; Nestler, EJ; Steiner, MA; Wotjak, CT | 1 |
Mitchell, PB; Morris, MJ | 1 |
Astrup, A; Bartels, EM; Bliddal, H; Christensen, R; Kristensen, PK | 1 |
Boekholdt, SM; Jukema, JW; Peters, RJ | 1 |
Cohen, AF; Dubois, EA; Pijl, H; van Bronswijk, H | 1 |
Nau, JY | 1 |
Al-Zaman, Y; Aylwin, S | 1 |
Forslund, T; Hjemdahl, P; Raaschou, P; Wettermark, B | 1 |
Després, JP; Pi-Sunyer, X; Scheen, A; Van Gaal, L | 1 |
Blüher, M | 1 |
Di Marzo, V; Szallasi, A | 1 |
7 review(s) available for sr141716 and Depression
Article | Year |
---|---|
Rimonabant and depression.
Topics: Alcoholism; Animals; Depression; Humans; Piperidines; Pyrazoles; Rimonabant | 2008 |
[Association of obesity and depression].
Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Appetite Regulation; Bipolar Disorder; Circadian Rhythm; Cyclobutanes; Depression; Depressive Disorder, Major; Dietary Carbohydrates; Energy Intake; Ghrelin; Humans; Hypothalamo-Hypophyseal System; Insulin Resistance; Leptin; Obesity; Piperidines; Pituitary-Adrenal System; Pyrazoles; Rimonabant; Seasonal Affective Disorder; Sleep Wake Disorders; Surveys and Questionnaires; Weight Gain; Weight Loss | 2008 |
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
Topics: Adult; Body Weight; Depression; Humans; Nausea; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Smoking Cessation; Smoking Prevention; Suicide | 2007 |
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
Topics: Adult; Body Weight; Depression; Humans; Nausea; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention; Suicide | 2007 |
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.
Topics: Anti-Obesity Agents; Anxiety Disorders; Depression; Double-Blind Method; Female; Humans; Male; Multicenter Studies as Topic; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Weight Loss | 2007 |
[The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
Topics: Cardiovascular Diseases; Depression; Diet, Reducing; Humans; Lipids; Obesity; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss | 2007 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide | 2008 |
3 trial(s) available for sr141716 and Depression
Article | Year |
---|---|
Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing.
Topics: Adult; Anxiety Disorders; Depression; Emotions; Female; Humans; Male; Memory, Short-Term; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Recognition, Psychology; Rimonabant; Young Adult | 2012 |
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.
Topics: Adolescent; Adult; Analysis of Variance; Cannabinoid Receptor Antagonists; Cognition Disorders; Depression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuropsychological Tests; Piperidines; Psychiatric Status Rating Scales; Pyrazoles; Rimonabant; Schizophrenia; Treatment Outcome; Young Adult | 2012 |
Depression and anxiety with rimonabant.
Topics: Anti-Obesity Agents; Anxiety; Depression; Humans; Meta-Analysis as Topic; Piperidines; Pyrazoles; Rimonabant | 2007 |
23 other study(ies) available for sr141716 and Depression
Article | Year |
---|---|
Subchronic Central Administration of Cannabinoid Ligands Modulates Nociception in Bulbectomized Rats.
Topics: Animals; Depression; Disease Models, Animal; Dronabinol; Ligands; Male; Nociception; Olfactory Bulb; Pain Threshold; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant | 2019 |
A translational rodent assay of affective biases in depression and antidepressant therapy.
Topics: Affect; Animals; Antidepressive Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Carbolines; Depression; Discrimination Learning; Disease Models, Animal; Environment; Isotretinoin; Male; Piperidines; Pyrazoles; Rats; Reward; Rimonabant; Stress, Psychological; Translational Research, Biomedical | 2013 |
Effects of rimonabant on the development of single dose-induced behavioral sensitization to ethanol, morphine and cocaine in mice.
Topics: Akathisia, Drug-Induced; Animals; Animals, Outbred Strains; Anxiety; Cannabinoid Receptor Antagonists; Central Nervous System Depressants; Cocaine; Depression; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Ethanol; Male; Mice; Morphine; Motor Activity; Narcotics; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Substance-Related Disorders | 2015 |
The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.
Topics: Animals; Anxiety; Behavior, Addictive; Behavior, Animal; Cannabinoid Receptor Antagonists; Cues; Depression; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Drug Inverse Agonism; Drug-Seeking Behavior; Male; Maze Learning; Mesencephalon; Motivation; Motor Activity; Piperidines; Pyrazoles; Rats, Long-Evans; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Swimming; Time Factors; Tobacco Use Cessation Devices; Tobacco Use Disorder; Weight Loss | 2016 |
A dual inhibitor of FAAH and TRPV1 channels shows dose-dependent effect on depression-like behaviour in rats.
Topics: Amidohydrolases; Animals; Antidepressive Agents; Arachidonic Acids; Behavior, Animal; Cannabinoid Receptor Antagonists; Depression; Dose-Response Relationship, Drug; Drug Inverse Agonism; Male; Piperidines; Prefrontal Cortex; Pyrazoles; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Serotonin; TRPV Cation Channels | 2017 |
Rimonabant: a rapidly expanding role in the management of metabolic and systemic disorders besides polycystic ovarian syndrome.
Topics: Cannabinoid Receptor Antagonists; Depression; Female; Humans; Metabolic Diseases; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant | 2009 |
Depression and weight loss: opposite outcome for surgery and rimonabant?
Topics: Anti-Obesity Agents; Depression; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Safety; Treatment Outcome; Weight Loss | 2008 |
The endocannabinoid system as a target for obesity treatment.
Topics: Amides; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Cyclobutanes; Depression; Endocannabinoids; Humans; Lactones; Life Style; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Pyridines; Rimonabant; Risk | 2008 |
Impairments in endocannabinoid signaling and depressive illness.
Topics: Affect; Anti-Obesity Agents; Antidepressive Agents; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Depression; Depressive Disorder; Endocannabinoids; Humans; Ligands; Obesity; Piperidines; Pyrazoles; Research; Rimonabant; Signal Transduction; Tobacco Use Disorder | 2009 |
Sub-chronic administration of rimonabant causes loss of antidepressive activity and decreases doublecortin immunoreactivity in the mouse hippocampus.
Topics: Animals; Anti-Obesity Agents; Behavior, Animal; Bromodeoxyuridine; Cell Count; Depression; Doublecortin Domain Proteins; Doublecortin Protein; Hippocampus; Immunohistochemistry; Male; Mice; Mice, Inbred ICR; Microtubule-Associated Proteins; Neurogenesis; Neurons; Neuropeptides; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Stress, Psychological | 2009 |
The effects of chronic administration of tranylcypromine and rimonabant on behaviour and protein expression in brain regions of the rat.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Element-Binding Protein; Depression; Drug Inverse Agonism; Frontal Lobe; Male; Monoamine Oxidase Inhibitors; Motor Activity; Nerve Tissue Proteins; Phosphorylation; Piperidines; Protein Processing, Post-Translational; Pyrazoles; Random Allocation; Rats; Rats, Inbred Strains; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Tranylcypromine | 2012 |
Antidepressant-like effects of Δ⁹-tetrahydrocannabinol and rimonabant in the olfactory bulbectomised rat model of depression.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cannabinoid Receptor Antagonists; Depression; Disease Models, Animal; Dronabinol; Frontal Lobe; Hippocampus; Male; MAP Kinase Signaling System; Olfactory Bulb; Piperidines; Pyrazoles; Rats; Rimonabant | 2012 |
Inhibitory effect of the antidepressant St. John's wort (hypericum perforatum) on rat bladder contractility in vitro.
Topics: Acetylcholine; Adenosine Triphosphate; Animals; Anthracenes; Antidepressive Agents; Atropine; Bridged Bicyclo Compounds; Capsaicin; Depression; Electric Stimulation; Female; Haloperidol; Hypericum; Kaempferols; Male; Methysergide; Muscle Contraction; Muscle, Smooth; Naloxone; Perylene; Phentolamine; Phloroglucinol; Piperidines; Plant Extracts; Propranolol; Pyrazoles; Quercetin; Rats; Rats, Wistar; Rimonabant; Rutin; Terpenes; Tetrodotoxin; Urinary Bladder; Urinary Incontinence; Verapamil | 2004 |
Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents.
Topics: Aggression; Analysis of Variance; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Behavior, Animal; Depression; Diazepam; Dose-Response Relationship, Drug; Electroshock; Emotions; Fluoxetine; Gerbillinae; Immobility Response, Tonic; Male; Maze Learning; Mice; Models, Animal; Neuropsychological Tests; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant | 2005 |
Effect of rimonabant on weight and cardiometabolic risk factors.
Topics: Anti-Obesity Agents; Anxiety; Depression; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors | 2006 |
Rimonabant in obese patients with type 2 diabetes.
Topics: Depression; Diabetes Mellitus, Type 2; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2007 |
Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice.
Topics: Adaptation, Psychological; Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Corticosterone; Depression; Desipramine; Disease Models, Animal; Female; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Statistics, Nonparametric; Stress, Psychological; Swimming; Time Factors | 2008 |
[New drugs; rimonabant].
Topics: Appetite Regulation; Cardiovascular Diseases; Depression; Diet, Reducing; Energy Intake; Humans; Lipids; Lipogenesis; Obesity; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss | 2007 |
[Antiobesity drugs--new limitations].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Depression; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Lactones; Obesity, Morbid; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Suicide; Weight Loss | 2007 |
[Still questions around the slimming agent rimobant. Not approved in USA because of the risk of mental adverse effects].
Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Depression; Drug Approval; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Weight Loss | 2007 |
Efficacy and safety of the weight-loss drug rimonabant.
Topics: Anti-Obesity Agents; Depression; Depressive Disorder, Major; Humans; Obesity; Patient Selection; Piperidines; Pyrazoles; Rimonabant; Suicide | 2008 |
Efficacy and safety of the weight-loss drug rimonabant.
Topics: Anti-Obesity Agents; Depression; Depressive Disorder, Major; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant | 2008 |
Rimonabant in rats with a metabolic syndrome: good news after the depression.
Topics: Animals; Anti-Inflammatory Agents; Body Weight; Depression; Disease Models, Animal; Inflammation Mediators; Leukocytes; Metabolic Syndrome; Piperidines; Platelet Activation; Platelet Aggregation Inhibitors; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant | 2008 |